BCSC was significantly presented in triple negative subtype breast cancer as there were 32 patients with the BCSC expression, and out of them, 15 patients (46.9%) had triple negative disease, 10 patients (31.3%) had the luminal subtype, and seven patients (21.9%) were Her2-amplified, while 44 patients were without the BCSC expression, and out of them, 30 patients (68.2%) were of the luminal subtype, no patient (20.5%) had triple negative disease, and five patients (11.4%) were Her2-amplified with (P 0.006), see Table 2. This evidence concerns the gene ERBB2 and breast cancer.